NEWSMedicago Announces A Proposed Offering of Units
3/24/2011 4:18:43 PM - NFD
QUEBEC CITY, QUEBEC, Mar 24, 2011 (Marketwire via COMTEX News Network) --
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
Medicago Inc. ("Medicago" or the "Company") (TSX:MDG), announced today that it has undertaken an overnight marketed offering of units, each unit being comprised of one common share and a portion of a common share purchase warrant, the offering to be effected in each of the Canadian provinces of British Columbia, Alberta, Ontario and Quebec by way of a prospectus supplement to Medicago's base shelf prospectus dated July 7, 2010. The number of units to be distributed, the price of each unit and the exercise price of each whole common share purchase warrant will be determined in context of the market, with final terms to be determined at the time of pricing. The syndicate is being co-led by Desjardins Capital Markets and Bloom Burton & Co., and includes Paradigm Capital Inc., Roth Capital Partners, LLC, Laurentian Bank Securities Inc. and RBC Capital Markets.
This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.
About Medicago
Medicago is a clinical-stage biotechnology company, developing effective and competitive vaccines based on proprietary Virus-Like Particles (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against pandemic and seasonal influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of the genetic sequence. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.